{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:41:51Z","timestamp":1786466511499,"version":"build-2736575974"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Hosp Pharm"],"abstract":"<jats:p>Background: Outpatient parenteral antimicrobial therapy (OPAT) is often used for patients who need long-term antimicrobial therapy. Meropenem is a broad-spectrum antibiotic used to treat polymicrobial and multidrug-resistant bacterial infections.\nObjective: To evaluate the efficacy, tolerance, and safety of IV meropenem for pediatric patients in the OPAT program at CHU Sainte- Justine in Montr\u00e9al, Quebec.\nMethods: At the study institution, meropenem solutions (1\u201340 mg\/mL) are prepared in polyvinylchloride bags or cassettes. Each delivery device contains one daily dose, and infusions (at room temperature) take place every 8 hours. Devices are delivered to the patient\u2019s home in batches every 3 or 4 days. With refrigeration, the drug solution has a short period of stability (96 hours). This single-centre retrospective study included all patients under 18 years of age who received IV meropenem therapy as part of the OPAT program between April 2000 and April 2024. For the current analysis, demographic data, clinical data, serum alanine aminotransferase levels, and white blood cell counts were collected using a standardized template.\nResults: A total of 349 courses of therapy (for 262 patients) met the inclusion criteria. For most patients, the treatments were successful and well tolerated, with an overall success rate of 93.4% (326\/349). Few gastrointestinal symptoms and rashes were reported. Neutropenia and eosinophilia were more frequently observed than in previous studies. OPAT-related adverse events were mainly catheter-related (8.9%, 31\/349) or pump-related (6.3%, 22\/349) issues.\nConclusions: These results suggest that IV meropenem can be safely and effectively used in pediatric OPAT, although the target concentration of 90% may not be retained, according to current stability data.\nKeywords: meropenem, outpatient parenteral antimicrobial therapy, safety, pediatric infections, antibiotics\nR\u00c9SUM\u00c9\nContexte : L\u2019antibioth\u00e9rapie intraveineuse (IV) \u00e0 domicile (ABAD) est souvent utilis\u00e9e chez les patients qui ont besoin d\u2019antibioth\u00e9rapie \u00e0 long terme. Le m\u00e9rop\u00e9nem est un antibiotique \u00e0 large spectre utilis\u00e9 pour traiter les infections polymicrobiennes et multir\u00e9sistantes.\nObjectif : \u00c9valuer l\u2019efficacit\u00e9, la tol\u00e9rance et l\u2019innocuit\u00e9 du m\u00e9rop\u00e9nem IV chez les patients p\u00e9diatriques du programme ABAD du CHU Sainte-Justine, \u00e0 Montr\u00e9al (Qu\u00e9bec).\nM\u00e9thodologie : Au CHU Saint-Justine, le m\u00e9rop\u00e9nem, \u00e0 une concentration variant de 1 \u00e0 40 mg\/mL, est conserv\u00e9 dans un sac en PVC ou une cassette. Chaque dispositif d\u2019administration contient une dose quotidienne et les perfusions (\u00e0 temp\u00e9rature ambiante) ont lieu toutes les 8 heures. Les dispositifs sont livr\u00e9s par lots tous les 3 \u00e0 4 jours au domicile des patients. Le m\u00e9rop\u00e9nem dans ces dispositifs a une courte dur\u00e9e de conservation de 96 heures au r\u00e9frig\u00e9rateur. Cette \u00e9tude r\u00e9trospective monocentrique a inclus tous les patients de moins de 18 ans ayant re\u00e7u du m\u00e9rop\u00e9nem intraveineux, dans le cadre du programme ABAD, entre avril 2000 et avril 2024. Pour cette analyse, les donn\u00e9es d\u00e9mographiques, les donn\u00e9es cliniques, les taux d\u2019alanine aminotransf\u00e9rase s\u00e9rique et la num\u00e9ration des globules blancs ont \u00e9t\u00e9 recueillis \u00e0 l\u2019aide d\u2019un formulaire standardis\u00e9.\nR\u00e9sultats : Au total, 349 traitements (administr\u00e9s \u00e0 262 patients) ont \u00e9t\u00e9 inclus dans l\u2019\u00e9tude. Ils ont \u00e9t\u00e9 efficaces et bien tol\u00e9r\u00e9s chez la plupart des patients, avec un succ\u00e8s global de 93,4 % (326\/349). Peu de sympt\u00f4mes gastro-intestinaux et d\u2019\u00e9ruptions cutan\u00e9es ont \u00e9t\u00e9 rapport\u00e9s. La neutrop\u00e9nie et l\u2019\u00e9osinophilie ont \u00e9t\u00e9 observ\u00e9es plus fr\u00e9quemment que dans les \u00e9tudes pr\u00e9c\u00e9dentes. Les effets ind\u00e9sirables li\u00e9s \u00e0 l\u2019ABAD concernaient principalement des probl\u00e8mes li\u00e9s au cath\u00e9ter (8,9 %, 31\/349) et \u00e0 l\u2019utilisation de la pompe (6,3 %, 22\/349).\nConclusions : Ces r\u00e9sultats semblent indiquer que le m\u00e9rop\u00e9nem IV est efficace et peut \u00eatre utilis\u00e9 en toute s\u00e9curit\u00e9 dans l\u2019ABAD p\u00e9diatrique, bien que la concentration cible de 90 % puisse ne pas \u00eatre atteinte dans tous les cas selon les donn\u00e9es de stabilit\u00e9 actuelles.\nMots-cl\u00e9s : m\u00e9rop\u00e9nem, antibioth\u00e9rapie intraveineuse \u00e0 domicile, s\u00e9curit\u00e9, infections p\u00e9diatriques, antibiotiques<\/jats:p>","DOI":"10.4212\/cjhp.3772","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:43:58Z","timestamp":1786459438000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, Tolerance, and Safety of Meropenem in a Pediatric Outpatient Parenteral Antimicrobial Therapy Program"],"prefix":"10.4212","volume":"78","author":[{"given":"Yu","family":"Shengyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na","family":"Co\u00efc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe-Alexandre","family":"Martineau-Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Forest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Chagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ovetchkine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Tapi\u00e9ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2732","published-online":{"date-parts":[[2025,7,9]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3772\/5672","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3772\/5673","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3772\/5672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:45:59Z","timestamp":1786463159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,10]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3772","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"e3772"}}